Trial Profile
Open, Randomized, Multinational Phase IIIb Trial Evaluating the Activity and Safety of Cetuximab as 250 mg/m2 Weekly and 500 mg/m2 Every Two Weeks Maintenance Therapy After Platinum-based Chemotherapy in Combination With Cetuximab as First-line Treatment for Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms NEXT
- Sponsors Merck KGaA
- 05 Oct 2021 Planned number of patients changed from 583 to 1200.
- 03 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.